These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16721048)

  • 1. Theoretical proposal: allele dosage of MAP2K4/MKK4 could rationalize frequent 17p loss in diverse human cancers.
    Cunningham SC; Gallmeier E; Hucl T; Dezentje DA; Abdelmohsen K; Gorospe M; Kern SE
    Cell Cycle; 2006 May; 5(10):1090-3. PubMed ID: 16721048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and mutation analyses of MKK4, a candidate tumour suppressor gene encoded by chromosome 17p, in human gastric adenocarcinoma.
    Chae KS; Ryu BK; Lee MG; Byun DS; Chi SG
    Eur J Cancer; 2002 Oct; 38(15):2048-57. PubMed ID: 12376211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss.
    Cunningham SC; Gallmeier E; Hucl T; Dezentje DA; Calhoun ES; Falco G; Abdelmohsen K; Gorospe M; Kern SE
    Cancer Res; 2006 Jun; 66(11):5560-4. PubMed ID: 16740690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
    Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
    Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.
    Spillman MA; Lacy J; Murphy SK; Whitaker RS; Grace L; Teaberry V; Marks JR; Berchuck A
    Gynecol Oncol; 2007 May; 105(2):312-20. PubMed ID: 17276500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
    J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of wild-type p53 in lichen sclerosus adjacent to human papillomavirus-negative vulvar cancer.
    Vanin K; Scurry J; Thorne H; Yuen K; Ramsay RG
    J Invest Dermatol; 2002 Nov; 119(5):1027-33. PubMed ID: 12445188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma.
    Grebe SK; McIver B; Hay ID; Wu PS; Maciel LM; Drabkin HA; Goellner JR; Grant CS; Jenkins RB; Eberhardt NL
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3684-91. PubMed ID: 9360526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between allelic imbalance on 17p, p53 mutation and p53 overexpression in head and neck cancer.
    Götte K; Riedel F; Neubauer J; Schäfer C; Coy JF; Hörmann K
    Int J Oncol; 2001 Aug; 19(2):331-6. PubMed ID: 11445847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
    Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
    Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
    Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
    PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor γ2 expression.
    Ahn YH; Yang Y; Gibbons DL; Creighton CJ; Yang F; Wistuba II; Lin W; Thilaganathan N; Alvarez CA; Roybal J; Goldsmith EJ; Tournier C; Kurie JM
    Mol Cell Biol; 2011 Nov; 31(21):4270-85. PubMed ID: 21896780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
    Kim HL; Vander Griend DJ; Yang X; Benson DA; Dubauskas Z; Yoshida BA; Chekmareva MA; Ichikawa Y; Sokoloff MH; Zhan P; Karrison T; Lin A; Stadler WM; Ichikawa T; Rubin MA; Rinker-Schaeffer CW
    Cancer Res; 2001 Apr; 61(7):2833-7. PubMed ID: 11306453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lip cancer and pre-cancerous lesions harbor TP53 mutations, exhibit allelic loss at 9p, 9q, and 17p, but no BRAFV600E mutations.
    Correa GT; Bernardes VF; de Sousa SF; Diniz MG; Salles JM; Souza RP; De-Paula AM; Gomez RS; Gomes CC
    Tumour Biol; 2015 Nov; 36(11):9059-66. PubMed ID: 26084614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas.
    Andersen TI; Gaustad A; Ottestad L; Farrants GW; Nesland JM; Tveit KM; Børresen AL
    Genes Chromosomes Cancer; 1992 Mar; 4(2):113-21. PubMed ID: 1373310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for another tumor suppressor gene at 17p13.3 distal to TP53 in hepatocellular carcinoma.
    Guan XY; Sham JS; Tai LS; Fang Y; Li H; Liang Q
    Cancer Genet Cytogenet; 2003 Jan; 140(1):45-8. PubMed ID: 12550757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer.
    Chen LC; Neubauer A; Kurisu W; Waldman FM; Ljung BM; Goodson W; Goldman ES; Moore D; Balazs M; Liu E
    Proc Natl Acad Sci U S A; 1991 May; 88(9):3847-51. PubMed ID: 1673792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chromosome arm 17p13.3: could HIC1 be the one ?].
    Chopin V; Leprince D
    Med Sci (Paris); 2006 Jan; 22(1):54-61. PubMed ID: 16386221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric brain tumors: loss of heterozygosity at 17p and TP53 gene mutations.
    Orellana C; Hernandez-Martí M; Martínez F; Castel V; Millán JM; Alvarez-Garijo JA; Prieto F; Badía L
    Cancer Genet Cytogenet; 1998 Apr; 102(2):93-9. PubMed ID: 9546059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.